In the News: Biotech Media Explained

So you want to keep up with biotech, but not by wading through dense journals or press releases written by lawyers for lawyers. Good news: biotech has a surprisingly lively media ecosystem. Even better: most of it is free (or at least freemium). Here’s your insider guide to the top ten (not in any particular order) biotech industry-focused media outlets as curated by Biotech Primer.

1. Endpoints News
   URL: endpointsnews.com
   Owned by: Financial Times (FT)
   Known for: Breaking biotech news at startup speed.
   Best at: Deals, pipelines, and industry gossip that turns out to be true.
   Cost: Free headlines; paid PRO tier for deeper reporting.
2. Fierce Biotech
   URL: fiercebiotech.com
   Owned by: Questex
   Known for: Fast, punchy headlines on financings, layoffs, pipelines, and drama.
   Best at: Answering “what just happened?” before your Slack explodes.
   Cost: Free (email newsletters included).
3. STAT News
   URL: statnews.com/category/biotech
   Owned by: Boston Globe Media
   Known for: Investigative biotech journalism with teeth.
   Best at: Policy, pricing, FDA scrutiny, and uncomfortable truths.
   Cost: Limited free; subscription required for full access.
   
4. The Cancer Letter
   URL: cancerletter.com
   Owned by: Independent
   Known for: Oncology, policy, and FDA coverage.
   Best at: Cancer-focused biotech intelligence.
   Cost: Paid subscription.
   
5. The Pharma Letter
   URL: thepharmaletter.com
   Owned by: Independent (UK-based)
   Known for: Global regulatory and market intelligence.
   Best at: Non-US perspectives.
   Cost: Subscription required.
   
6. Labiotech.eu
   URL: labiotech.eu
   Owned by: Labiotech GmbH
   Known for: Europe’s biotech pulse.
   Best at: Startups, innovation, and EU biotech trends.
   Cost: Free.
   
   
   
   
   
7. BioPharma Dive
   URL: biopharmadive.com
   Owned by: Industry Dive (Informa)
   Known for: Executive-level analysis without the academic headache.
   Best at: Strategy, regulation, and “why this matters.”
   Cost: Free.
8.  Nature Biotechnology
   URL: nature.com/nbt
   Owned by: Springer Nature
   Known for: Science + business credibility.
   Best at: Deep dives into platform technologies.
   Cost: Subscription (some free articles).
9. The Scientist
   URL: the-scientist.com
   Owned by: LabX Media Group
   Known for: Science for those in the field.
   Best at: Research trends and tools.
   Cost: Free.
10. BioSpace
    URL: biospace.com
    Owned by: Diversified Communications
    Known for: The intersection of biotech news and biotech jobs.
    Best at: Company updates, funding news, and career intelligence.
    Cost: Free.
    

Why This Matters

Today’s biotech coverage is built on explainers, sharp headlines, and fast context because the audience is no longer just scientists. It’s investors, lawyers, consultants, marketers, and career-switchers who need to understand the science without going back for a degree. That’s exactly the crowd Biotech Primer’s Biotech for Non-Scientists Subscription was built for. Our microcourses give the scientific foundation to actually follow the headlines, connect the dots, and sound smart in the room. Read the news with confidence by test-driving our subscription, free for three days.

Bottom line

If biotech had a morning paper, this would be it. Mix two fast news sites, one deep-thinker, and one global lens and you’ll sound impressively informed before your second coffee. Better yet, skimming just a few of these daily will help you spot trends before they show up in earnings calls, investor decks, or conference buzzwords. In biotech, being early is half the advantage.